The Indian Pharmacopoeia Commission (IPC) signed a Memorandum of Understanding with the Uttar Pradesh Promote Pharma Council (UPPPC) on July 14, 2026, to reinforce quality standards and regulatory compliance across the pharmaceutical and medical device sectors. The agreement was formalised during the YEIDA MedTech Investors Meet and Site Visit 2026 at the India Expo Mart in Greater Noida. This partnership aligns with Uttar Pradesh’s aggressive push to transform itself from a consumer state into a major manufacturing hub for pharmaceuticals and medical technology.
What Does the MoU Cover?
Under the agreement, IPC and UPPPC will work together on multiple fronts to improve the quality ecosystem of drugs and medical devices in Uttar Pradesh. A central focus is promoting awareness of the Indian Pharmacopoeia (IP), the Pharmacovigilance Programme of India (PvPI), and the Materiovigilance Programme of India (MvPI) among manufacturers, healthcare professionals, and regulators in the state.
The two bodies will organise joint training programmes, workshops, and stakeholder awareness initiatives to build capacity across the sector. The MoU also encourages research, innovation, and stronger collaboration between industry and academic institutions. To support micro, small, and medium enterprises (MSMEs), digital tools for adverse event reporting will be made available, helping smaller manufacturers meet regulatory requirements more easily. Patient safety will be strengthened through better quality assurance and post-market surveillance mechanisms.
The partnership is expected to help Uttar Pradesh build a more competitive pharmaceutical and medical technology ecosystem while reinforcing safety standards for end consumers.
Who Are the Signatories?
Indian Pharmacopoeia Commission (IPC)
The IPC is an autonomous institution under the Ministry of Health and Family Welfare, established in 2005 and fully operational from January 1, 2009. It is headquartered in Sector-23, Raj Nagar, Ghaziabad, Uttar Pradesh. Its core mandate is to set and update quality standards for drugs manufactured, sold, and consumed in India, as required under the Drugs and Cosmetics Act, 1940.
IPC publishes the Indian Pharmacopoeia (IP), the official book of drug standards, whose latest ninth edition was released in 2022 with over 3,000 monographs. It also publishes the National Formulary of India (NFI), a guidance document for healthcare professionals on the rational use of medicines.
Beyond standard-setting, IPC operates the Pharmacovigilance Programme of India (PvPI), launched in July 2010, which monitors adverse drug reactions across the country. In 2017, IPC’s National Coordination Centre for PvPI was designated a WHO Collaborating Centre for Pharmacovigilance in Public Health Programmes and Regulatory Services. IPC also runs the Materiovigilance Programme of India (MvPI), which tracks adverse events related to medical devices.
Uttar Pradesh Promote Pharma Council (UPPPC)
The UPPPC is a state government company incorporated in December 2024 under the Registrar of Companies, Kanpur, with its registered office at the Biotech Park, Kursi Road, Lucknow. It serves as the nodal agency for implementing Uttar Pradesh’s vision of becoming a leading destination for pharmaceutical, biotechnology, and medical device manufacturing.
UPPPC has been at the centre of several recent state-level initiatives, including the Promote Pharma initiative announced in March 2025, which offers subsidies, tax exemptions, and infrastructure support to attract pharma investments. It also coordinates with central agencies such as the Department of Biotechnology’s BIRAC to accelerate innovation and startup growth in the life sciences sector. The council manages the UP Integrated Medical Research Application System (UPIMRAS), a digital platform for streamlining clinical research approvals in the state.
Why This Partnership Matters for UP’s Pharma Ambitions
Uttar Pradesh, despite being India’s most populous state and its largest pharmaceutical consumer market, currently produces only about 2% of its own medicine requirement. The state government has launched a multi-pronged strategy to close this gap and establish UP as a nationally significant pharma manufacturing hub.
The centrepiece of this push is the Bulk Drug Pharma Park in Lalitpur, spread across 1,472 acres in the Bundelkhand region and expected to attract investments exceeding ₹12,000 crore. Phase I covers 353 acres dedicated to formulation units, bulk drugs, and common infrastructure. A 350-acre Medical Device Park is being developed by YEIDA in Sector 28, Greater Noida, with an approved project cost of ₹439.49 crore including central assistance of ₹100 crore. This park has already attracted interest from major companies such as Wipro GE, Philips, Siemens, and Panacea. Additionally, a 250-acre Pharma Formulation Park is planned in Sector 7 near the upcoming Noida International Airport at Jewar.
The YEIDA MedTech Investors Meet, where this MoU was signed, itself generated investment commitments worth ₹500 crore for 12 new medical device manufacturing units. The event showcased UP’s integrated approach combining infrastructure development, policy incentives under the UP Pharmaceutical and Medical Device Industry Policy, 2023, and regulatory handholding through agencies like UPPPC.
The IPC-UPPPC MoU adds a crucial quality assurance layer to this infrastructure push. Without robust quality standards and regulatory compliance capacity, even the best-equipped manufacturing parks cannot produce globally competitive products. IPC’s expertise in pharmacopoeial standards, drug safety monitoring, and medical device vigilance gives UP’s manufacturers a ready pathway to meet both domestic and international quality benchmarks.
India’s Pharmaceutical Landscape: A Broader View
India’s pharmaceutical exports, valued at nearly $27.8 billion, are expected to cross $30 billion soon, while the domestic pharma market stands at $60 billion and is projected to double to $130 billion by 2030. The country manufactures over 60% of the world’s vaccines and supplies medicines to more than 200 countries. The medical device sector is growing at a robust 15 to 20% annually, with domestic production increasing its share of local demand from 10% to 30% over the last five years.
Partnerships like the IPC-UPPPC MoU reflect a broader trend of centre-state collaboration in healthcare manufacturing. Similar agreements have been signed between IPC and state-level bodies in other regions, focusing on pharmacovigilance capacity building, rational medicine use, and quality compliance. This decentralised approach helps translate national standards into ground-level implementation across state ecosystems, making India’s quality assurance framework more resilient as the country scales up its pharmaceutical production capacity.
Key Takeaways
- The Indian Pharmacopoeia Commission (IPC) signed an MoU with the Uttar Pradesh Promote Pharma Council (UPPPC) on July 14, 2026 during the YEIDA MedTech Investors Meet at India Expo Mart, Greater Noida.
- IPC is an autonomous institution under the Ministry of Health and Family Welfare, established in 2005, and headquartered in Ghaziabad, Uttar Pradesh.
- IPC operates the Pharmacovigilance Programme of India (PvPI), launched in 2010, and was designated a WHO Collaborating Centre for pharmacovigilance in 2017.
- The MoU focuses on strengthening quality standards, regulatory compliance, pharmacovigilance, materiovigilance, and patient safety while supporting MSMEs through digital adverse event reporting tools.
- Uttar Pradesh, which currently produces only 2% of its medicine requirement, is developing a 1,472-acre Bulk Drug Pharma Park in Lalitpur (targeting ₹12,000 crore investment) and a 350-acre Medical Device Park in YEIDA (project cost ₹439.49 crore).
